Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice

    Research output: Contribution to journalReviewResearchpeer-review

  2. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low versus High Carbohydrate Diet in Type 1 Diabetes: A 12-week randomized open-label crossover study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Liraglutide preserved insulin secretion in adults with newly diagnosed type 1 diabetes: the NewLira trial

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations

Elevated levels of non-esterified fatty acids (NEFA) play a role in insulin resistance, impaired beta-cell function and they are a denominator of the abnormal atherogenic lipid profile that characterizes obese patients with type 2 diabetes (T2DM). We hypothesized that the GLP-1 receptor agonist liraglutide, in combination with metformin, would reduce lipolysis. In a randomized, double-blind, placebo-controlled, cross-over trial, 41 T2DM patients with coronary artery disease were randomized and treated with liraglutide-metformin vs placebo-metformin during 12- + 12-week periods with a wash-out period of at least 2 weeks before and between the intervention periods. NEFA kinetics were estimated using the Boston Minimal Model of NEFA metabolism, with plasma NEFA and glucose levels measured during a standard 180-minute frequently sampled intravenous glucose tolerance test. Liraglutide-metformin reduced estimates of lipolysis. Furthermore, placebo-metformin increased estimates of lipid oxidation, while treatment with liraglutide eliminated this effect. We conclude that liraglutide exerts a clinically relevant reduction in estimates of lipolysis and lipid oxidation which is explained, in part, by improved insulin secretion, as revealed by an intravenous glucose tolerance test.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume21
Issue number8
Pages (from-to)2012-2016
Number of pages5
ISSN1462-8902
DOIs
Publication statusPublished - Aug 2019

Bibliographical note

© 2019 John Wiley & Sons Ltd.

    Research areas

  • clinical trial, GLP-1 analogue, liraglutide, metformin, randomised trial, type 2 diabetes

ID: 57091373